Glycogen synthase kinase 3β inhibition reduces the development of nonseptic shock induced by zymosan in mice

Salvatore Cuzzocrea, Rosanna Di Paola, Emanuela Mazzon, Concetta Crisafulli, Tiziana Genovese, Carmelo Muià, Maha Abdelrahman, Emanuela Esposito, Christoph Thiemermann

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Glycogen synthase kinase 3 has recently been identified as a ubiquitous serine-threonine protein kinase that participates in a multitude of cellular processes and plays an important role in the pathophysiology of a number of diseases. In the present study, we have investigated the effects of 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), a glycogen synthase kinase 3β inhibitor, on the development of nonseptic shock caused by zymosan (dose, 500 mg/kg i.p. suspension in saline) in mice. Organ failure and systemic inflammation in mice was assessed 18 h after administration of zymosan and/or TDZD-8; another group of mice was monitored for 12 days (for clinical score and mortality). Treatment of mice with TDZD-8 (dose, 10 mg/kg i.p., 1 and 6 h after zymosan administration) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan. TDZD-8 also attenuated the lung, liver, and pancreatic injury, the renal dysfunction caused by zymosan, and the increase in myeloperoxidase activity caused by zymosan in the lung and in the intestine. Immunohistochemical analysis for inducible nitric oxide synthase, nitrotyrosine, poly(ADP-ribose), CD30, CD30 ligand, and Fas ligand revealed positive staining in lung and intestinal tissues obtained from zymosan-injected mice. The degree of staining for inducible nitric oxide synthase, nitrotyrosine, poly(ADP-ribose), CD30, CD30 ligand, and Fas ligand were markedly reduced in tissue sections obtained from zymosan-injected mice that had received TDZD-8. This study provides the first evidence that TDZD-8 attenuates the degree of zymosan-induced, nonseptic shock in mice.

Original languageEnglish
Pages (from-to)97-107
Number of pages11
JournalShock
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Glycogen Synthase Kinase 3
Zymosan
Shock
CD30 Ligand
Poly Adenosine Diphosphate Ribose
Fas Ligand Protein
Nitric Oxide Synthase Type II
Lung
Staining and Labeling
Protein-Serine-Threonine Kinases
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
Peroxidase
Intestines
Cell Movement
Suspensions
Inflammation
Kidney

Keywords

  • Cytokines
  • GSK-3β
  • Inducible nitric oxide synthase
  • Inflammation
  • Nitric oxide
  • TDZD-8
  • Zymosan-induced multiple-organ failure

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Physiology

Cite this

Glycogen synthase kinase 3β inhibition reduces the development of nonseptic shock induced by zymosan in mice. / Cuzzocrea, Salvatore; Di Paola, Rosanna; Mazzon, Emanuela; Crisafulli, Concetta; Genovese, Tiziana; Muià, Carmelo; Abdelrahman, Maha; Esposito, Emanuela; Thiemermann, Christoph.

In: Shock, Vol. 27, No. 1, 01.2007, p. 97-107.

Research output: Contribution to journalArticle

Cuzzocrea, S, Di Paola, R, Mazzon, E, Crisafulli, C, Genovese, T, Muià, C, Abdelrahman, M, Esposito, E & Thiemermann, C 2007, 'Glycogen synthase kinase 3β inhibition reduces the development of nonseptic shock induced by zymosan in mice', Shock, vol. 27, no. 1, pp. 97-107. https://doi.org/10.1097/01.shk.0000235084.56100.71
Cuzzocrea, Salvatore ; Di Paola, Rosanna ; Mazzon, Emanuela ; Crisafulli, Concetta ; Genovese, Tiziana ; Muià, Carmelo ; Abdelrahman, Maha ; Esposito, Emanuela ; Thiemermann, Christoph. / Glycogen synthase kinase 3β inhibition reduces the development of nonseptic shock induced by zymosan in mice. In: Shock. 2007 ; Vol. 27, No. 1. pp. 97-107.
@article{afabd05cd82647d184462e934f18dc82,
title = "Glycogen synthase kinase 3β inhibition reduces the development of nonseptic shock induced by zymosan in mice",
abstract = "Glycogen synthase kinase 3 has recently been identified as a ubiquitous serine-threonine protein kinase that participates in a multitude of cellular processes and plays an important role in the pathophysiology of a number of diseases. In the present study, we have investigated the effects of 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), a glycogen synthase kinase 3β inhibitor, on the development of nonseptic shock caused by zymosan (dose, 500 mg/kg i.p. suspension in saline) in mice. Organ failure and systemic inflammation in mice was assessed 18 h after administration of zymosan and/or TDZD-8; another group of mice was monitored for 12 days (for clinical score and mortality). Treatment of mice with TDZD-8 (dose, 10 mg/kg i.p., 1 and 6 h after zymosan administration) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan. TDZD-8 also attenuated the lung, liver, and pancreatic injury, the renal dysfunction caused by zymosan, and the increase in myeloperoxidase activity caused by zymosan in the lung and in the intestine. Immunohistochemical analysis for inducible nitric oxide synthase, nitrotyrosine, poly(ADP-ribose), CD30, CD30 ligand, and Fas ligand revealed positive staining in lung and intestinal tissues obtained from zymosan-injected mice. The degree of staining for inducible nitric oxide synthase, nitrotyrosine, poly(ADP-ribose), CD30, CD30 ligand, and Fas ligand were markedly reduced in tissue sections obtained from zymosan-injected mice that had received TDZD-8. This study provides the first evidence that TDZD-8 attenuates the degree of zymosan-induced, nonseptic shock in mice.",
keywords = "Cytokines, GSK-3β, Inducible nitric oxide synthase, Inflammation, Nitric oxide, TDZD-8, Zymosan-induced multiple-organ failure",
author = "Salvatore Cuzzocrea and {Di Paola}, Rosanna and Emanuela Mazzon and Concetta Crisafulli and Tiziana Genovese and Carmelo Mui{\`a} and Maha Abdelrahman and Emanuela Esposito and Christoph Thiemermann",
year = "2007",
month = "1",
doi = "10.1097/01.shk.0000235084.56100.71",
language = "English",
volume = "27",
pages = "97--107",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Glycogen synthase kinase 3β inhibition reduces the development of nonseptic shock induced by zymosan in mice

AU - Cuzzocrea, Salvatore

AU - Di Paola, Rosanna

AU - Mazzon, Emanuela

AU - Crisafulli, Concetta

AU - Genovese, Tiziana

AU - Muià, Carmelo

AU - Abdelrahman, Maha

AU - Esposito, Emanuela

AU - Thiemermann, Christoph

PY - 2007/1

Y1 - 2007/1

N2 - Glycogen synthase kinase 3 has recently been identified as a ubiquitous serine-threonine protein kinase that participates in a multitude of cellular processes and plays an important role in the pathophysiology of a number of diseases. In the present study, we have investigated the effects of 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), a glycogen synthase kinase 3β inhibitor, on the development of nonseptic shock caused by zymosan (dose, 500 mg/kg i.p. suspension in saline) in mice. Organ failure and systemic inflammation in mice was assessed 18 h after administration of zymosan and/or TDZD-8; another group of mice was monitored for 12 days (for clinical score and mortality). Treatment of mice with TDZD-8 (dose, 10 mg/kg i.p., 1 and 6 h after zymosan administration) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan. TDZD-8 also attenuated the lung, liver, and pancreatic injury, the renal dysfunction caused by zymosan, and the increase in myeloperoxidase activity caused by zymosan in the lung and in the intestine. Immunohistochemical analysis for inducible nitric oxide synthase, nitrotyrosine, poly(ADP-ribose), CD30, CD30 ligand, and Fas ligand revealed positive staining in lung and intestinal tissues obtained from zymosan-injected mice. The degree of staining for inducible nitric oxide synthase, nitrotyrosine, poly(ADP-ribose), CD30, CD30 ligand, and Fas ligand were markedly reduced in tissue sections obtained from zymosan-injected mice that had received TDZD-8. This study provides the first evidence that TDZD-8 attenuates the degree of zymosan-induced, nonseptic shock in mice.

AB - Glycogen synthase kinase 3 has recently been identified as a ubiquitous serine-threonine protein kinase that participates in a multitude of cellular processes and plays an important role in the pathophysiology of a number of diseases. In the present study, we have investigated the effects of 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), a glycogen synthase kinase 3β inhibitor, on the development of nonseptic shock caused by zymosan (dose, 500 mg/kg i.p. suspension in saline) in mice. Organ failure and systemic inflammation in mice was assessed 18 h after administration of zymosan and/or TDZD-8; another group of mice was monitored for 12 days (for clinical score and mortality). Treatment of mice with TDZD-8 (dose, 10 mg/kg i.p., 1 and 6 h after zymosan administration) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan. TDZD-8 also attenuated the lung, liver, and pancreatic injury, the renal dysfunction caused by zymosan, and the increase in myeloperoxidase activity caused by zymosan in the lung and in the intestine. Immunohistochemical analysis for inducible nitric oxide synthase, nitrotyrosine, poly(ADP-ribose), CD30, CD30 ligand, and Fas ligand revealed positive staining in lung and intestinal tissues obtained from zymosan-injected mice. The degree of staining for inducible nitric oxide synthase, nitrotyrosine, poly(ADP-ribose), CD30, CD30 ligand, and Fas ligand were markedly reduced in tissue sections obtained from zymosan-injected mice that had received TDZD-8. This study provides the first evidence that TDZD-8 attenuates the degree of zymosan-induced, nonseptic shock in mice.

KW - Cytokines

KW - GSK-3β

KW - Inducible nitric oxide synthase

KW - Inflammation

KW - Nitric oxide

KW - TDZD-8

KW - Zymosan-induced multiple-organ failure

UR - http://www.scopus.com/inward/record.url?scp=33845697130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845697130&partnerID=8YFLogxK

U2 - 10.1097/01.shk.0000235084.56100.71

DO - 10.1097/01.shk.0000235084.56100.71

M3 - Article

C2 - 17172987

AN - SCOPUS:33845697130

VL - 27

SP - 97

EP - 107

JO - Shock

JF - Shock

SN - 1073-2322

IS - 1

ER -